The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Van Voorhees Seth since 2006.
This trader's CIK number is 1284934.
At the time of last reporting, Van Voorhees Seth was the CHIEF FINANCIAL OFFICER of Nrx Pharmaceuticals, Inc.. (stock ticker symbol NRXP).
Also see all insider trading activities at Nrx Pharmaceuticals, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2017 | REFR | 4,000 | $4,600 | 0 | $0 | 0 | $0 |
2014 | REFR | 2,000 | $10,900 | 0 | $0 | 0 | $0 |
2011 | REFR | 24,000 | $207,600 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2022 | NRXP | 16,337 | $18,134 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2006 | APFC | 20,893 | $115,564 | 0 | $0 | 0 | $0 |
1. Research Frontiers Inc (REFR)
2. Nrx Pharmaceuticals, Inc. (NRXP)
3. American Pacific Corp (APFC)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2017-09-12 | REFR | Buy | 4,000 | 1.15 | 4,600 |
2014-06-19 | REFR | Buy | 2,000 | 5.45 | 10,900 |
2011-02-10 | REFR | Buy | 24,000 | 8.65 | 207,600 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2022-11-25 | NRXP | Buy | 16,337 | 1.11 | 18,134 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2006-03-01 | APFC | Buy | 5,893 | 5.71 | 33,649 |
2006-02-17 | APFC | Buy | 15,000 | 5.46 | 81,915 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Van Voorhees Seth (CHIEF FINANCIAL OFFICER of Nrx Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.